Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review.

ABSTRACT: Treatments for alopecia areata (AA) have traditionally been prescribed off-label, and there has been no universal agreement on how to best manage the condition. Baricitinib is the first oral selective Janus kinase (JAK) inhibitor approved for the treatment of adults with severe AA. As a better understanding of the evidence supporting the management of AA in clinical practice is needed, we conducted a systematic literature review and subsequent narrative review to describe available evidence pertaining to the efficacy and tolerability of treatments currently recommended for adults with moderate-to-severe forms of AA. From 2557 identified records, a total of 53 records were retained for data extraction: 9 reported data from 7 randomized controlled trials (RCTs) versus placebo, and 44 reporte

SUBMITTER: Egeberg A 

PROVIDER: S-EPMC10689337 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature